Clinical Trial Update: A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating latanoprostene bunod for ocular hypertension was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension

Drugs mentioned

• LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION, 0.024% (latanoprostene bunod ophthalmic solution 0.024%)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Ocular Hypertension | Phase 4 | Status: WITHDRAWN